Pneumoconiosis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Pneumoconiosis is any lung condition caused by inhaling organic or inorganic airborne dust and fibers. Typically encountered in occupational settings, where patients are exposed to such particulates, it is classified as an occupational disease. The commonly encountered forms of pneumoconiosis include asbestosis, silicosis, and coal miner's lung. These conditions lead to inflammation and fibrosis within the lung, leading to irreversible lung damage. Prevention relies on effectively managing workplace exposure and adhering to health and safety regulations. The condition initiates with an inflammatory reaction to inhaled foreign particles, stimulating macrophages, lymphocytes, and epithelial cells. These cells subsequently release various inflammatory mediators such as interleukin-1 beta, TNF-alpha, matrix metalloproteinases, and transforming growth factor-beta. Fibroblasts are then activated to proliferate and encapsulate the dust particles, forming nodules. Chest radiographs serve as the primary diagnostic tool for assessing the presence and extent of pneumoconiosis. Over time, these nodules can progress to extensive fibrosis, characteristic of conditions like coal workers' pneumoconiosis and silicosis. Treatment typically involves inhaled medications such as bronchodilators or corticosteroids to manage symptoms.
- The prevalence of pneumoconiosis ranges between 412 and 833 per 100,000. The highest prevalence was among those ≥75 years of age, males, Whites, and North American Natives. Most claims (70.0%–72.5%) included an ICD-CM diagnosis code for asbestosis.
Thelansis’s “Pneumoconiosis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Pneumoconiosis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Pneumoconiosis across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Pneumoconiosis Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment